Hostname: page-component-77c89778f8-cnmwb Total loading time: 0 Render date: 2024-07-18T16:02:53.644Z Has data issue: false hasContentIssue false

Hypertriglyceridemia and Lower LDL Cholesterol Concentration in Relation to Apolipoprotein E Phenotypes in Myotonic Dystrophy

Published online by Cambridge University Press:  18 September 2015

Sital Moorjani*
Affiliation:
Lipid Research Unit, Le Centre Hospitalier de l'Université Laval
Daniel Gaudet
Affiliation:
Human Genetics, Le Centre Hospitalier de l'Université Laval
Claude Laberge
Affiliation:
Human Genetics, Le Centre Hospitalier de l'Université Laval
Marie Christine Thibault
Affiliation:
Human Genetics, Le Centre Hospitalier de l'Université Laval
Jean Mathieu
Affiliation:
Human Genetics, Le Centre Hospitalier de l'Université Laval
Jean Morissette
Affiliation:
Muscular Dystrophy Clinic, Hôpital de Chicoutimi
Paul J. Lupien
Affiliation:
Lipid Research Unit, Le Centre Hospitalier de l'Université Laval
Daniel Brun
Affiliation:
Lipid Research Unit, Le Centre Hospitalier de l'Université Laval
Claude Gagné
Affiliation:
Lipid Research Unit, Le Centre Hospitalier de l'Université Laval
*
Lipid Research Unit, Le Centre Hospitalier de l'Université Laval, 2705 Boulevard Laurier, Sainte-Foy, Québec, Canada G1V 4G2
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Plasma lipid, lipoprotein levels and apolipoprotein apo E phenotypes were determined in 70 patients with myotonic dystrophy (MyD) and 81 controls. Marked differences were noticed in the apo E phenotype frequencies between the two groups. Plasma triglycerides and VLDL cholesterol were higher in MyD than controls, but only the latter was related to differences in the apo E phenotypes between two groups. Accordingly, the ratio of VLDL cholesterol/plasma triglycerides was increased significantly in MyD, suggesting accumulation of intermediary density particles due to lower affinity of E2 containing lipoproteins for lipoprotein cell receptors. The LDL cholesterol concentration was lower in MyD than controls and was related to differences in the apo E phenotype frequencies between the two groups. These results indicate increased removal of LDL particles in the apo E2 phenotypes, perhaps due to upregulation of LDL (B, E) receptor activity. Plasma cholesterol and HDL cholesterol concentrations were similar in both groups. Another feature of the study was lower levels of plasma cholesterol, triglycerides, VLDL and LDL cholesterol in the homozygous E4:E4 phenotype. These results suggest increased clearance rate of both VLDL and LDL particles and support the concept that apo E4-containing lipoproteins have higher in vivo affinity for ape E and/or B, E receptors.

Type
SPECIAL SUPPLEMENT Dystrophie myotonique au Québec
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1.Laberge, C, Gaudet, D, Morissette, J, et al. Linkage of myotonic dystrophy and apo E in a French Canadian isolate. Cytogenet Cell Genet 1985; 81: 675676.Google Scholar
2.Zannis, VI, Breslow, JL, Utermann, G, et al. Proposed nomenclature of apo E isoproteins, apo E genotypes and phenotypes. J Lipid Res 1982; 23: 911914.CrossRefGoogle ScholarPubMed
3.Sing, CE, Davignon, J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268285.Google ScholarPubMed
4.Mahley, RW, Innerarity, TL. Lipoprotein receptors and cholesterol hemostasis. Biochim Biophys Acta 1983; 737: 197222.CrossRefGoogle Scholar
5.Wakamatsu, H, Nakamura, H, Ito, K, et al. Concentration and fatty acid composition of serum lipids in myotonia dystrophica. Horm Metab Res 1972; 4: 458462.CrossRefGoogle ScholarPubMed
6.Poffenbarger, PL, Pozefsky, T, Soeldner, JS. The direct relationship of proinsulin-insulin hypersecretion to basal serum levels of cholesterol and triglycerides in myotonic dystrophy. J Lab Clin Med 1976; 87: 384396.Google ScholarPubMed
7.Moorjani, S, Gagné, C, Lupien, P-J, et al. Plasma triglycerides related decrease in high density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism 1986; 35: 311316.CrossRefGoogle ScholarPubMed
8.Mathieu, J, Simard, M, DeBrackeleer, M, et al. Partial syndrome of myotonic dystrophy: clinical presentation and follow-up. Can J Neurol Sci, 1989; 16: 99103.CrossRefGoogle ScholarPubMed
9.Havel, RJ, Eder, HA, Bragdon, HA. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 13451353.CrossRefGoogle ScholarPubMed
10.Utermann, G, Hess, M, Vogelberg, KH. Broad-beta disease (hyperlipoproteinemia type III): Genetics, gene frequency and diagnosis without ultracentrifugation. In: Radola, BJ, Graesslin, D, eds. Electrofocusing and isotacophoresis. Berlin, Walter de Gruyter 1977; pp 281293.Google Scholar
11.Malik, N, Berrie, A. New stain fixative for proteins separated by gel isoelectric focusing based on Commassie brilliant blue. Anal Biochem 1972; 49: 173176.CrossRefGoogle Scholar
12.Rifkind, BM, Segal, P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. J Amer Med Assoc 1983; 250: 18691872.CrossRefGoogle ScholarPubMed
13.Utermann, G, Kinderman, I, Kaffarnik, H, Steinmetz, A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Gent 1984; 65: 232236.CrossRefGoogle ScholarPubMed
14.Gregg, RE, Zech LA Schaefer, EJ, et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986; 78: 815821.CrossRefGoogle ScholarPubMed
15.Hudson, AJ, Huff, MW, Wright, CG, et al. The role of insulin resistance in the pathogenesis of myotonic muscular dystrophy. Brain 1987; 110: 469488.CrossRefGoogle ScholarPubMed
16.Steiner, G. Hypertriglyceridemia and carbohydrate intolerance: interrelations and therapeutic implications. Am J Cardiol 1986; 57: 27G–30G.CrossRefGoogle ScholarPubMed
17.Harper, PS. Myotonic dystrophy. Philadelphia: WB Saunders Co 1979.Google Scholar
18.Howard, BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613628.CrossRefGoogle ScholarPubMed
19.Eto, M, Watanabe, K, Iwashima, Y, et al. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics. Diabetes 1986; 35: 13741382.CrossRefGoogle ScholarPubMed
20.Eto, M, Watanabe, K, Ischii, K. Reciprocal effects of apolipoprotein E alleles (ε2 and ε4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986; 29: 477484.CrossRefGoogle Scholar
21.Weintraub, MS, Eisenberg, S, Breslow, JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 1987; 80: 15711577.CrossRefGoogle ScholarPubMed
22.Ghiselli, G, Schaefer, EJZech, LA, et al. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest 1982; 70: 474477.CrossRefGoogle ScholarPubMed
23.Smit, M, Kooij-Meijs, EVD, Frants, RR, et al. Apolipoprotein genecluster on chromosome 19: Definite localization of apo C2 gene and the polymorphic Hpal site associated with type III hyperlipoproteinemia. Human Genet 1988; 78: 9093.CrossRefGoogle Scholar